Home › Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
 

Keywords :   


Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors

2015-08-13 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & HOUSTON Clinical Trials to Evaluate Mercks KEYTRUDA (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and The University of Texas MD Anderson Cancer Center today announced that they have entered into a strategic clinical research collaboration to evaluate Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel antitumor medicines. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orMD Anderson Media Relations:Ron Gilmore, 713-745-1898Rlgilmore1@mdanderson.org Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: center research solid cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.05Eastern North Pacific Tropical Weather Outlook
21.05Atlantic Tropical Weather Outlook
20.05Dantex USA appoints Rob Tolland VP of sales
20.05USDA moves to electronic identification tags
20.05Better pasture and hay conditions anticipated for 2024
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05Producers to be paid grid premiums for AngusLink Beef Scores
More »